Document is current
Any future updates will be listed below
-
Authors
Zimmerman, Maxwell I.
Porter, Justin R. http://orcid.org/0000-0002-0340-951X
Ward, Michael D.
Singh, Sukrit http://orcid.org/0000-0003-1914-4955
Vithani, Neha
Meller, Artur
Mallimadugula, Upasana L.
Kuhn, Catherine E.
Borowsky, Jonathan H. http://orcid.org/0000-0002-0761-3585
Wiewiora, Rafal P.
Hurley, Matthew F. D.
Harbison, Aoife M.
Fogarty, Carl A. http://orcid.org/0000-0001-5333-8206
Coffland, Joseph E.
Fadda, Elisa
Voelz, Vincent A.
Chodera, John D. http://orcid.org/0000-0003-0542-119X
Bowman, Gregory R. http://orcid.org/0000-0002-2083-4892
-
Funding
Funding for this research was provided by:
NIH: national institute of healthNSF: national science foundation
NIH: National institute of health
- License Information
-
More Information
Article History
Received: 6 October 2020
Accepted: 14 April 2021
First Online: 24 May 2021
Competing interests
: J.D.C. is a current member of the scientific advisory board of OpenEye Scientific Software and a consultant to Foresite Laboratories. The Chodera laboratory receives or has received funding from multiple sources, including the National Institutes of Health, the National Science Foundation, the Parker Institute for Cancer Immunotherapy, Relay Therapeutics, Entasis Therapeutics, Silicon Therapeutics, EMD Serono (Merck KGaA), AstraZeneca, Vir Biotechnology, Bayer, XtalPi, the Molecular Sciences Software Institute, the Starr Cancer Consortium, the Open Force Field Consortium, Cycle for Survival, a Louis V. Gerstner Young Investigator Award and the Sloan Kettering Institute. A complete funding history for the Chodera lab can be found at .
Free to read: This content has been made available to all.
